Gast A, Dietemann-Molard A, Pelletier A, Pauli G, Bieth J G
INSERM U 237, Université Louis Pasteur de Strasbourg, Faculté de Pharmacie, Illkirch, France.
Am Rev Respir Dis. 1990 Apr;141(4 Pt 1):880-3. doi: 10.1164/ajrccm/141.4_Pt_1.880.
The present study was aimed at testing whether alpha 1-proteinase inhibitor-sufficient patients with lung emphysema or idiopathic spontaneous pneumothorax have an impaired antielastase protection at the lung alveolar level. We have collected bronchoalveolar lavage fluids (BALF) from 20 PIMM emphysematous patients (44 +/- 12 yr), 24 patients with pneumothorax but no radiologic evidence of emphysema (30 +/- 11 yr), 32 healthy subjects (27 +/- 6 yr), and 56 patients with sarcoidosis (30 +/- 11 yr). The BALF were assayed for immunoreactive albumin, alpha 1-proteinase inhibitor (alpha 1PI), leukocyte elastase-alpha 1PI complex (LE-alpha 1PI), and mucus proteinase inhibitor (MPI) as well as for porcine pancreatic elastase inhibitory capacity, a measure of active alpha 1PI. The healthy subjects and the patients with emphysema or pneumothorax had comparable levels of total and active alpha 1PI and total MPI. In contrast, the levels of LE-alpha 1PI complex were elevenfold higher in patients with emphysema than in normal subjects (p = 0.021) and tended to increase with the severity of the disease because they were negatively correlated with FEV1/FVC% (r = -0.55; 0.05 less than p less than 0.1). They did not vary with age in a population of patients with sarcoidosis (r = 0.03), suggesting that their eleven-fold increase in emphysematous patients is not related to the age of these subjects. Patients with pneumothorax had levels of LE-alpha 1PI complex that did not significantly differ from those of normal subjects (p = 0.24).(ABSTRACT TRUNCATED AT 250 WORDS)
本研究旨在测试α1-蛋白酶抑制剂充足的肺气肿或特发性自发性气胸患者在肺泡水平的抗弹性蛋白酶保护功能是否受损。我们收集了20例蛋白酶抑制剂充足的肺气肿患者(44±12岁)、24例气胸但无肺气肿影像学证据的患者(30±11岁)、32例健康受试者(27±6岁)和56例结节病患者(30±11岁)的支气管肺泡灌洗液(BALF)。对BALF检测免疫反应性白蛋白、α1-蛋白酶抑制剂(α1PI)、白细胞弹性蛋白酶-α1PI复合物(LE-α1PI)、黏液蛋白酶抑制剂(MPI)以及猪胰弹性蛋白酶抑制能力(活性α1PI的一种测量指标)。健康受试者以及肺气肿或气胸患者的总α1PI和活性α1PI以及总MPI水平相当。相比之下,肺气肿患者的LE-α1PI复合物水平比正常受试者高11倍(p = 0.021),且往往随疾病严重程度增加,因为它们与FEV1/FVC%呈负相关(r = -0.55;0.05<p<0.1)。在结节病患者群体中,它们不随年龄变化(r = 0.03),这表明肺气肿患者中其升高11倍与这些受试者的年龄无关。气胸患者的LE-α1PI复合物水平与正常受试者无显著差异(p = 0.24)。(摘要截短至250字)